Holoprosencephaly Agnathia

Holoprosencephaly–agnathia is a very rare birth defect that affects both the brain and the face. In early pregnancy (about weeks 3–4), the front part of the brain should split into right and left halves, and the lower jaw should form from tissues in the midline of the face and neck. In holoprosencephaly, that front brain does not fully divide. In agnathia, the lower jaw is missing or extremely small. When these two problems happen together, the baby may have a single fused brain ventricle or poorly separated brain halves, along with a very small mouth, tongue that falls back, and little or no lower jaw. The airway can be blocked. Feeding is hard. Other organs may also be affected. The condition usually results from errors in “midline patterning” signals—especially the sonic hedgehog (SHH) pathway—that guide early embryo development. The severity ranges from very severe (life-limiting) to rare partial forms, but most cases are severe.

Holoprosencephaly (HPE) means the front part of the brain (forebrain) does not fully split into two halves during very early pregnancy. This can affect brain structure and face formation. Agnathia means the lower jaw (mandible) is very small or missing. When both occur together, the baby can have severe breathing and feeding problems, and facial differences like very small or absent jaw, small mouth opening, tongue position problems, ear position changes, and sometimes midline facial changes. Body systems can also be affected, including hormones (pituitary), heart, and gut. Severity varies widely. Some babies pass away before or soon after birth. Others live longer with strong supportive care, surgery to protect the airway and feeding, seizure control, hormone support, and ongoing therapy. Families also need strong emotional and social support.

Other names

This condition is also called agnathia–holoprosencephaly sequence (AHS). Doctors may also use agnathia–otocephaly sequence or agnathia-otocephaly complex when the ears sit abnormally low or toward the midline and the mouth opening is small (microstomia). Older terms you might see include agnathia–microstomia–synotia complex (meaning no jaw, small mouth, ears near the midline). In some reports it is described simply as holoprosencephaly with agnathia or HPE-agnathia.

Types

By brain involvement (holoprosencephaly subtypes).

1. Alobar HPE: the most severe form. The front brain does not split at all. There is one big cavity and fused deep brain structures. Facial defects are usually very severe.

2. Semilobar HPE: partial separation of the brain. Some division occurs toward the back, but the front stays fused.

3. Lobar HPE: the halves are mostly separated. Subtle midline defects remain.

4. Middle interhemispheric (syntelencephaly): the middle parts fail to split, while front and back may separate.

By jaw involvement (agnathia spectrum).

1. Complete agnathia: almost no lower jaw forms. The mouth is tiny or closed, the tongue may be malpositioned, and the airway is at risk.

2. Extreme micrognathia: a very small jaw that functions poorly, often grouped with agnathia because the airway and feeding risks are similar.

3. Agnathia–otocephaly pattern: agnathia with very small mouth and ears positioned abnormally close together or near the lower face midline.

By combined pattern (brain + face).

1. Classic sequence: severe HPE (often alobar) plus complete agnathia and airway obstruction.

2. Partial sequence: milder HPE (lobar or middle interhemispheric) plus extreme micrognathia.

3. Syndromic association: HPE–agnathia along with other organ malformations (heart, kidneys, limbs).

---

Causes

1. Pathway disruption of SHH (sonic hedgehog).
   SHH is a master signal that tells midline brain and face tissues how to form. If SHH signaling is too weak or blocked, the brain may not split in two and the lower jaw tissue does not pattern correctly, leading to HPE–agnathia.

2. Mutations in the SHH gene itself.
   Changes in the SHH gene can directly reduce the signal needed for normal midline development. The effect can range from mild facial changes to severe HPE with agnathia.

3. Mutations in ZIC2.
   ZIC2 controls early neural plate development. Faults here disturb how the front brain edges fold and separate, and they can indirectly disrupt jaw growth.

4. Mutations in SIX3.
   SIX3 helps set up the forebrain and eye field. Variants can cause severe holoprosencephaly and may be paired with lower face and jaw underdevelopment.

5. Mutations in TGIF1.
   TGIF1 regulates genes that keep embryonic signals in balance. If it is faulty, midline patterning can fail, contributing to HPE and jaw defects.

6. Mutations in GLI2.
   GLI2 carries the SHH message into the nucleus. When it does not work well, the SHH pathway signal is weak, which may cause HPE and craniofacial anomalies including agnathia or severe micrognathia.

7. Mutations in PTCH1.
   PTCH1 is the SHH receptor. Faults can misread SHH levels and reduce downstream signaling, disturbing both brain separation and jaw formation.

8. Mutations in CDON (a SHH co-receptor).
   CDON helps cells “hear” SHH. Loss of this helper reduces the signal strength that midline tissues need and has been linked to HPE and facial midline defects.

9. NODAL/FOXH1 pathway defects.
   These signals set the body axis very early. If they are abnormal, the head midline can form poorly, increasing risk for HPE and jaw underdevelopment.

10. Chromosome aneuploidy (e.g., trisomy 13).
    Extra genetic material, especially in trisomy 13, often causes HPE and severe facial anomalies. Agnathia or extreme micrognathia can be part of this pattern.

11. Triploidy (an entire extra set of chromosomes).
    Triploidy disrupts many developmental programs at once and is strongly associated with severe brain and facial malformations, including HPE–agnathia.

12. Microdeletions/microduplications involving midline genes (e.g., 7q36 near SHH).
    Small missing or extra DNA segments can silence key midline genes. The outcome is variable but can include HPE and agnathia.

13. Smith–Lemli–Opitz syndrome (low cholesterol, DHCR7 defect).
    Cholesterol is needed to activate SHH. In SLOS, very low cholesterol weakens SHH signaling and can cause HPE with craniofacial defects.

14. Maternal pre-gestational diabetes.
    High glucose during organ formation is a known risk for midline defects. Poorly controlled diabetes in very early pregnancy increases the chance of HPE and severe jaw anomalies.

15. Alcohol exposure in early pregnancy.
    Alcohol can interfere with many growth signals and is linked to midline facial anomalies. Severe exposure very early may contribute to HPE–agnathia in some cases.

16. Retinoic acid (isotretinoin) exposure.
    Excess retinoic acid disturbs head patterning signals. Early exposure is a strong teratogen and can lead to HPE and jaw defects.

17. Exposure to SHH-blocking plant toxins (e.g., cyclopamine).
    Cyclopamine directly blocks SHH signaling. While human exposure is rare, the biological lesson is clear: blocking SHH during weeks 3–4 can cause cyclopia, HPE, and jaw malformations.

18. Certain anti-seizure medicines (e.g., valproate) in early organogenesis.
    Some antiepileptics can raise the risk of midline defects. The overall risk depends on drug, dose, timing, and folate status.

19. Severe early intrauterine infections (rare association).
    A few reports link early, severe infections to midline disruption. This is uncommon, but damage during the critical window could contribute.

20. Multifactorial/unknown with possible recessive inheritance.
    In many families no single cause is found. A combination of hidden gene changes and early environmental factors likely explains these cases; consanguinity can raise the chance of recessive gene defects.

---

Symptoms and clinical features

1. Very small or absent lower jaw (agnathia/extreme micrognathia).
   The chin is missing or extremely small. The mouth may not open well. This causes feeding and breathing trouble.

2. Very small mouth (microstomia).
   The opening is narrow. It is hard to place a nipple or tube. Oral suction is weak.

3. Tongue falling backward (glossoptosis).
   The tongue sits back in the throat because the jaw is small. This narrows the airway and worsens obstruction, especially when the baby lies on the back.

4. Breathing difficulty at birth.
   Stridor, noisy breathing, or pauses in breathing can occur because the face and jaw do not support a clear airway.

5. Feeding problems.
   Poor latch and weak suck are common. Swallowing may be unsafe, with milk entering the airway. Weight gain can be poor.

6. Apnea or blue spells (cyanosis).
   Brief stops in breathing and low oxygen can occur due to airway blockage or brainstem instability in severe HPE.

7. Eye spacing problems or a single midline eye in extreme cases.
   Close-set eyes (hypotelorism) are common. In the most severe form, one eye field or cyclopia may occur.

8. Nose abnormalities.
   The nose may be tiny, single-nostril, or replaced by a midline proboscis in severe HPE.

9. Cleft lip and/or cleft palate.
   The midline of the upper lip and the roof of the mouth may not fuse, adding to feeding and airway problems.

10. Ear anomalies (synotia).
    Ears can be low, rotated, or located toward the lower face midline. Hearing may be affected.

11. Seizures.
    Abnormal electrical activity in the brain can occur in HPE. Seizures may appear in the newborn period or later.

12. Low muscle tone (hypotonia).
    Weak tone reflects central nervous system involvement and complicates feeding and breathing.

13. Endocrine instability (pituitary/hypothalamic dysfunction).
    HPE can disrupt the pituitary. Babies may have low sodium or high urine output (diabetes insipidus), temperature swings, or low blood sugar.

14. Developmental delay in rare survivors.
    When a baby survives infancy, developmental challenges are common and usually severe.

15. Other organ defects.
    Heart, kidney, spine, or limb malformations may accompany HPE–agnathia, adding medical complexity.

---

Diagnostic tests

A) Physical examination

1. Comprehensive newborn exam.
   The clinician inspects the face, mouth, jawline, eyes, nose, and ears, and listens to the heart and lungs. The overall pattern—severe jaw deficiency plus midline facial features—raises strong suspicion for HPE–agnathia.

2. Airway observation at rest and with gentle stimulation.
   Providers watch for chest retractions, stridor, color changes, and breathing pauses. Worsening obstruction when supine suggests glossoptosis on a tiny jaw.

3. Feeding and suck–swallow assessment at the bedside.
   A careful trial with colostrum or sterile water looks for poor latch, coughing, gagging, or bluish color, which suggest unsafe swallowing.

4. Craniofacial anthropometry.
   Simple measurements and photos document jaw length, mouth width, eye spacing, and ear position to define severity and guide imaging and genetic testing.

5. Neurologic exam.
   Tone, reflexes, level of alertness, and signs of seizure activity are checked. Findings support concern for underlying holoprosencephaly.

B) Manual/bedside functional tests

6. Positioning and jaw-thrust airway test.
   Gentle repositioning (prone or side-lying) and manual jaw-thrust help judge how much the airway improves when the tongue is pulled forward.

7. Bedside flexible nasopharyngoscopy (when safe).
   A thin scope allows a quick look at the nose, pharynx, and larynx to see where the blockage is and whether the tongue base occludes the airway.

8. Clinical swallow evaluation by speech-language therapist.
   Structured feeding with careful observation helps decide if thickened feeds or tube feeding are needed and whether aspiration is likely.

9. Developmental reflex testing.
   Checking Moro, grasp, rooting, and suck reflexes provides a quick window on brainstem function in the context of HPE.

C) Laboratory and pathological tests

10. Chromosome analysis (karyotype).
    This looks for whole-chromosome problems like trisomy 13 or triploidy, which are strongly linked to HPE with severe facial anomalies.

11. Chromosomal microarray (CMA).
    CMA searches for small missing or extra DNA segments (microdeletions/duplications), including regions that contain SHH and other midline genes.

12. Targeted holoprosencephaly gene panel.
    A blood test sequences known HPE genes (e.g., SHH, ZIC2, SIX3, TGIF1, GLI2, PTCH1, CDON, others). Finding a variant can confirm the pathway involved and inform recurrence risk.

13. Exome or genome sequencing (if panel is negative).
    Broader testing can discover rare or new gene changes in midline pathways such as SHH and NODAL/FOXH1 signaling.

14. Metabolic and maternal labs (context-based).
    Infant cholesterol and 7-dehydrocholesterol (for SLOS), thyroid and pituitary hormones, electrolytes, and, for mothers, early-pregnancy A1c or charted glucose control help clarify contributing risks.

D) Electrodiagnostic/physiologic tests

15. Electroencephalogram (EEG).
    EEG records brain electrical activity. It helps diagnose seizures and background slowing that often accompany severe HPE.

16. Brainstem auditory evoked response (BAER/ABR).
    Clicks in the ear produce brainstem signals. Abnormal waves suggest hearing pathway or brainstem dysfunction, guiding hearing and airway plans.

17. Continuous pulse oximetry and cardiorespiratory monitoring.
    These bedside monitors track oxygen and heart rate patterns, revealing apnea spells, desaturations, or obstructive events during feeds and sleep.

E) Imaging tests

18. Prenatal ultrasound (first and second trimester).
    Ultrasound can show failure of brain division, a single ventricle, abnormal facial midline, and extreme jaw underdevelopment. Polyhydramnios may be present because the fetus cannot swallow well.

19. Fetal MRI (usually after 20–22 weeks).
    MRI gives clearer pictures of the brain midline, corpus callosum, and face. It helps define HPE subtype and the extent of jaw and airway anomalies before birth.

20. Postnatal brain MRI and craniofacial CT.
    MRI confirms the HPE subtype and checks the pituitary and other structures. Low-dose CT maps the facial bones to plan airway and feeding strategies and to document the degree of agnathia.

Non-pharmacological treatments

1. Airway positioning and safe sleep training
   Description: Nurses and therapists teach gentle head/neck positions, shoulder rolls, and side-lying that keep the tongue from falling back when the jaw is tiny or absent. Families learn to watch breathing effort, chest movement, and color. Specialized pillows are avoided in infants; instead, careful manual positioning and frequent checks are used.
   Purpose: Reduce airway blockage.
   Mechanism: Gravity and neck alignment enlarge the airway space behind the tongue.
   Benefits: Fewer desaturation spells, calmer feeding, safer rest.

2. Nasopharyngeal airway care (when prescribed)
   Description: A soft tube placed by clinicians can bypass tongue-base obstruction. Parents learn suction technique, humidification, and how to watch for blockage.
   Purpose: Keep airflow open without immediate surgery.
   Mechanism: Creates a stable channel for air entry.
   Benefits: Better oxygenation, time to plan long-term airway strategy.

3. Tracheostomy care education (post-surgery)
   Description: If a tracheostomy is required, caregivers learn tube changes, suctioning, humidification, emergency decannulation response, and infection signs.
   Purpose: Maintain a reliable airway at home.
   Mechanism: Direct airway access bypasses upper-airway collapse.
   Benefits: Safer breathing, fewer ER visits, more stable growth.

4. Feeding therapy (speech-language pathology)
   Description: Stepwise program for oral-motor skills, nipple choice, flow control, pacing, and safe swallow strategies. If oral feeding is unsafe, therapists still build non-nutritive suck and oral comfort.
   Purpose: Improve nutrition and reduce aspiration.
   Mechanism: Trains coordinated suck-swallow-breath; adapts tools to baby’s facial anatomy.
   Benefits: Better weight gain, fewer pneumonias, more comfort with feeds.

5. Thickened feeds and paced bottle techniques
   Description: Medical team may advise thickening formula/breast milk and slowing flow; caregivers count swallows and offer frequent pauses.
   Purpose: Lower aspiration risk.
   Mechanism: Slower movement of thicker liquid gives more time to close the airway.
   Benefits: Less coughing/choking, improved intake.

6. Gastrostomy (G-tube) care training (if placed)
   Description: Families learn stoma hygiene, tube securement, venting, and pump use. Therapists can still give gentle oral stimulation to support future skills.
   Purpose: Reliable nutrition when oral route is unsafe.
   Mechanism: Direct stomach access avoids unsafe swallow.
   Benefits: Better growth, fewer hospitalizations for dehydration.

7. Physiotherapy 1—Airway clearance techniques
   Description: Gentle chest physiotherapy, supported cough training as child grows, and suction education.
   Purpose: Reduce mucus plugging.
   Mechanism: Mobilizes secretions toward larger airways for removal.
   Benefits: Fewer infections, easier breathing.

8. Physiotherapy 2—Postural control and head-neck stability
   Description: Graded exercises (tummy time with supports, midline head control, later trunk control) tailored to neurologic level.
   Purpose: Safer feeding and breathing posture.
   Mechanism: Strengthens extensor and deep neck stabilizers.
   Benefits: Better airway patency, progress in gross motor milestones.

9. Physiotherapy 3—Oral-facial stimulation
   Description: Light stroking, vibration tools (if recommended), and jaw/tongue patterning to improve oral awareness.
   Purpose: Support eventual oral intake and speech sounds.
   Mechanism: Sensory input builds neural pathways for coordination.
   Benefits: Better tolerance of oral care and therapies.

10. Physiotherapy 4—Chest wall mobility and breathing patterning
    Description: Gentle rib mobility work and diaphragmatic cueing.
    Purpose: Improve ventilation efficiency.
    Mechanism: Encourages diaphragm use and reduces accessory muscle strain.
    Benefits: More stable oxygen levels, better endurance.

11. Physiotherapy 5—Contracture prevention
    Description: Positioning, splints as needed, and range-of-motion plans for limbs.
    Purpose: Keep joints flexible in children with limited mobility.
    Mechanism: Regular stretch prevents shortening.
    Benefits: Comfort, easier caregiving, better seating later.

12. Physiotherapy 6—Seizure-aware mobility coaching
    Description: Therapists plan safe movement around seizure triggers (lighting, fatigue), and teach caregivers how to guard joints during events.
    Purpose: Safer handling.
    Mechanism: Anticipates risk moments.
    Benefits: Fewer injuries, confidence at home.

13. Physiotherapy 7—Positioning for reflux relief
    Description: Upright holding after feeds, left-side lying when advised, avoiding sudden pressure on belly.
    Purpose: Reduce vomiting and aspiration.
    Mechanism: Gravity helps keep stomach contents down.
    Benefits: Better comfort, weight gain.

14. Physiotherapy 8—Assistive seating and mobility
    Description: Custom seats with head/neck support; later, strollers or wheelchairs with trunk supports.
    Purpose: Safe participation in daily life.
    Mechanism: External supports replace weak postural muscles.
    Benefits: Comfort, interaction, learning time.

15. Physiotherapy 9—Caregiver body-mechanic training
    Description: Lifting, turning, and bathing techniques that protect caregiver and child.
    Purpose: Prevent caregiver injury.
    Mechanism: Teaches neutral spine and leverage.
    Benefits: Sustainable home care.

16. Physiotherapy 10—Sensory regulation program
    Description: Predictable routines, low-stim environments if seizures or irritability worsen with overload.
    Purpose: Reduce stress and triggers.
    Mechanism: Calms the autonomic system.
    Benefits: Better sleep and feeding.

17. Mind-body 1—Parental stress, grief, and coping support
    Description: Counseling, peer groups, brief mindfulness, and structured problem-solving.
    Purpose: Reduce caregiver burnout.
    Mechanism: Lowers stress hormones, supports resilience.
    Benefits: Better decision-making, steadier home care.

18. Mind-body 2—Sleep hygiene coaching
    Description: Fixed routines, gentle dimming, quieting house sounds, safe sleep rules.
    Purpose: Improve child and parent sleep.
    Mechanism: Stabilizes circadian rhythm.
    Benefits: Fewer night events, daytime energy.

19. Educational therapy 1—Early intervention program
    Description: Local early-childhood services coordinate PT/OT/SLP and special instruction from infancy.
    Purpose: Maximize development.
    Mechanism: Frequent, targeted practice builds skills.
    Benefits: Best possible function for the child.

20. Educational therapy 2—Augmentative communication (as child grows)
    Description: Simple picture boards, eye-gaze systems, or switches.
    Purpose: Enable expression despite oral motor limits.
    Mechanism: Alternative pathways for communication.
    Benefits: Less frustration, more learning.

21. Feeding/OT—Oral desensitization plan
    Description: Stepwise exposure to tastes, temperatures, and textures, coordinated with swallow safety.
    Purpose: Build oral comfort.
    Mechanism: Controlled sensory input reduces gag/aversion.
    Benefits: More pleasant care and therapy.

22. Family genetics counseling (“gene-informed” education)
    Description: Review chromosome and gene results (if found), inheritance chance, and future pregnancy planning.
    Purpose: Clear information for the family.
    Mechanism: Risk assessment and options.
    Benefits: Informed decisions and support.

23. Respiratory therapy—Humidification and secretion management
    Description: Heated humidifiers for trach users, saline nebulization when ordered.
    Purpose: Keep secretions thin.
    Mechanism: Moist air loosens mucus.
    Benefits: Easier suction, fewer plugs.

24. Social work—Home equipment and benefits navigation
    Description: Help with supplies, home nursing, transport, and financial supports.
    Purpose: Reduce logistic strain.
    Mechanism: Connects to programs and coverage.
    Benefits: Stability at home.

25. Palliative care alongside active care
    Description: Symptom control and goals-of-care talks while still pursuing surgeries and therapies.
    Purpose: Maximize comfort and meaning.
    Mechanism: Team coordinates pain, breathlessness, sleep, and family values.
    Benefits: Better quality of life for child and family.

---

Drug treatments

1. Levetiracetam — Antiseizure (SV2A modulator).
   Dose/Time: Common pediatric start ~10–20 mg/kg/day divided twice; titrate per neurology.
   Purpose: Control seizures common in HPE.
   Mechanism: Modulates synaptic vesicle protein to stabilize neuronal firing.
   Side effects: Irritability, somnolence; rare mood changes.

2. Phenobarbital — Barbiturate antiseizure.
   Dose: Loading per weight; maintenance often ~3–5 mg/kg/day (specialist sets).
   Purpose: Neonatal seizures.
   Mechanism: Enhances GABA-A inhibition.
   Side effects: Sedation, respiratory depression, hypotension, bone effects with long use.

3. Topiramate — Antiseizure.
   Dose: ~1–3 mg/kg/day divided; slow titration.
   Purpose: Adjunct seizure control.
   Mechanism: Multiple (GABA enhancement, AMPA antagonism, carbonic anhydrase inhibition).
   Side effects: Appetite/weight changes, metabolic acidosis, kidney stones.

4. Valproate — Antiseizure.
   Dose: Specialist only; avoid in females of child-bearing potential later due to teratogenicity.
   Purpose: Broad-spectrum seizure control.
   Mechanism: Increases GABA; modulates sodium/calcium channels.
   Side effects: Liver toxicity, thrombocytopenia, weight gain, tremor.

5. Levothyroxine — Thyroid hormone.
   Dose: Weight-based mcg/kg/day; frequent labs.
   Purpose: Treat hypothyroidism from pituitary involvement.
   Mechanism: Replaces T4.
   Side effects: Over- or under-replacement symptoms (tachycardia, poor growth, etc.).

6. Hydrocortisone — Glucocorticoid replacement.
   Dose: Physiologic mg/m²/day divided; stress dosing during illness.
   Purpose: Adrenal insufficiency.
   Mechanism: Replaces cortisol.
   Side effects: Hyperglycemia, infection risk with high doses.

7. Desmopressin (DDAVP) — Antidiuretic hormone analog.
   Dose: Specialist dosing (intranasal/oral) with strict sodium checks.
   Purpose: Central diabetes insipidus (excess urination, sodium swings).
   Mechanism: V2 receptor agonist concentrates urine.
   Side effects: Hyponatremia if over-treated; seizures if sodium shifts.

8. Growth hormone (somatropin) — Endocrine therapy (selected cases).
   Dose: Pediatric endocrinologist sets IU/m²/week.
   Purpose: GH deficiency with poor growth.
   Mechanism: Replaces GH to support linear growth.
   Side effects: Intracranial hypertension (rare), edema, glucose effects.

9. Omeprazole / Esomeprazole — Proton pump inhibitors.
   Dose: mg/kg/day per GI.
   Purpose: Reflux and esophagitis prevention.
   Mechanism: Blocks gastric acid secretion.
   Side effects: GI upset, infection risk with prolonged use.

10. Ranitidine alternatives (e.g., famotidine) — H2 blocker.
    Dose: mg/kg/day in divided doses.
    Purpose: Reflux symptom relief (when PPI not suitable).
    Mechanism: H2 receptor blockade lowers acid.
    Side effects: Headache, rare liver enzyme changes.

11. Glycopyrrolate — Anticholinergic for drooling/secretions.
    Dose: mcg/kg/dose 2–3×/day (strict specialist oversight).
    Purpose: Reduce pooling secretions that worsen airway.
    Mechanism: Blocks muscarinic receptors in salivary glands.
    Side effects: Dry mouth, constipation, urinary retention.

12. Hypertonic saline nebulization (when ordered)
    Class: Airway osmotic therapy.
    Dose: 3–7% saline via neb per RT order.
    Purpose: Loosen thick secretions.
    Mechanism: Draws water into airway mucus.
    Side effects: Cough, bronchospasm (pre-bronchodilator sometimes used).

13. Albuterol (salbutamol) neb/inhaler — Bronchodilator.
    Dose: Per RT/pediatrician protocol.
    Purpose: Bronchospasm relief; easier airflow.
    Mechanism: β2-agonist relaxes airway muscle.
    Side effects: Tremor, tachycardia.

14. Melatonin (sleep aid)
    Class: Chronobiotic.
    Dose: Low mg dose at night per pediatrician.
    Purpose: Sleep regulation when schedule dysregulated.
    Mechanism: Mimics pineal melatonin to set circadian rhythm.
    Side effects: Morning drowsiness, rare vivid dreams.

15. Analgesia plan (acetaminophen)
    Class: Analgesic/antipyretic.
    Dose: mg/kg/dose with max daily limit.
    Purpose: Pain/fever relief post-procedures.
    Mechanism: Central COX modulation.
    Side effects: Liver toxicity if overdosed.

---

Dietary molecular supplements

(Evidence-informed support; not curative. Always clear with the medical team, especially with seizures or endocrine issues.)

1. DHA (docosahexaenoic acid)
   Dose: Pediatric formula with DHA or ~10–20 mg/kg/day when age-appropriate.
   Function/Mechanism: Structural omega-3 in neuronal membranes; may support visual and cognitive development.

2. Choline
   Dose: Age-appropriate intake via formula/foods or supplement per dietitian.
   Mechanism: Precursor for acetylcholine and phospholipids; supports brain development.

3. Folate (for mothers—preconception/prenatal)
   Dose: 400–800 mcg/day; higher if high-risk per OB.
   Mechanism: One-carbon metabolism for neural development; prevention focus.

4. Vitamin D
   Dose: Usual infant supplementation per guidelines.
   Mechanism: Bone and immune function; supports muscle and respiratory strength indirectly.

5. Iron
   Dose: Guided by labs.
   Mechanism: Hemoglobin and myelin enzymes; supports oxygen delivery.

6. Vitamin B12
   Dose: Only if deficient or low intake.
   Mechanism: Myelin and DNA synthesis.

7. Zinc
   Dose: Dietitian-guided.
   Mechanism: Enzyme cofactor for growth and immunity.

8. Iodine
   Dose: Appropriate iodized salt in family diet; targeted in infant nutrition.
   Mechanism: Thyroid hormone synthesis.

9. L-Carnitine
   Dose: Specialist-guided in suspected mitochondrial involvement.
   Mechanism: Fatty acid transport into mitochondria; may aid energy metabolism.

10. Probiotics (selected strains)
    Dose: Pediatric strains per GI.
    Mechanism: Gut barrier and microbiome support; may reduce GI infections/diarrhea.

---

Immunity booster / regenerative / stem-cell drugs

There are no approved immune-booster medicines or stem-cell treatments that cure holoprosencephaly-agnathia. Below are research-area explanations to prevent misinformation:

1. Mesenchymal stem cells (MSCs): Investigational for neuroprotection in other settings; not proven for HPE or jaw absence; risks include ectopic growth and immune reactions.

2. Neural stem cells: Prenatal/infant brain engraftment is experimental and ethically complex; not a clinical option.

3. Gene therapy for SHH/ZIC2/SIX3 variants: Conceptually interesting but no clinical therapy exists for correcting early forebrain patterning after birth.

4. Growth-factor infusions (e.g., IGF-1): Limited uses in specific syndromes; not established for HPE-agnathia.

5. “Immune boosters” (OTC blends): No evidence; may interact with meds and cause harm.

6. Platelet-rich plasma or exosomes: Experimental and not indicated here.
   Bottom line: Use supportive, airway, feeding, endocrine, and seizure care; consider clinical trials only through reputable centers and ethics boards.

---

Surgeries

1. Tracheostomy
   Procedure: Surgical creation of an opening in the windpipe with a tube.
   Why: Secure airway when jaw absence or tongue position blocks breathing.

2. Gastrostomy tube (G-tube)
   Procedure: Tube placed through the abdomen into the stomach.
   Why: Reliable nutrition and medication delivery when swallowing is unsafe.

3. Mandibular reconstruction (staged)
   Procedure: Using grafts (rib/iliac) and later distraction osteogenesis if anatomy allows; long-term staged plan.
   Why: Build a functional lower jaw to improve airway, feeding, and facial support.

4. Cleft and soft-tissue repairs
   Procedure: Repair of lip/palate or soft-tissue slings to improve mouth seal and function.
   Why: Better feeding, speech development, and hygiene.

5. CSF shunt (selected cases with hydrocephalus)
   Procedure: Ventriculoperitoneal shunt to drain cerebrospinal fluid.
   Why: Reduce pressure, protect brain tissue, improve comfort.

---

Preventions

1. Preconception folate daily.

2. Tight diabetes control before and during pregnancy.

3. Avoid alcohol in pregnancy.

4. Avoid known teratogens (e.g., isotretinoin/retinoic acids) under medical guidance.

5. Manage maternal PKU and other metabolic disorders.

6. Quit tobacco/vaping; avoid secondhand smoke.

7. Review all supplements/herbals with OB; avoid unregulated products.

8. Vaccinations as advised (e.g., rubella prevention reduces congenital risks generally).

9. Early prenatal care with targeted ultrasound.

10. Genetic counseling if prior history or abnormal screening.

---

When to see doctors urgently

• Breathing difficulty: fast breathing, chest pulling in, bluish lips/skin.

• Choking, coughing or color change with feeds; suspected aspiration.

• Fever, lethargy, poor arousal, dehydration (dry mouth, no tears, very few wet diapers).

• Seizure signs: stiffening, jerking, staring, loss of awareness.

• Vomiting with poor weight gain or blood-stained vomit.

• Unusual sleepiness or irritability, or any sudden change from baseline.

• Any tracheostomy or G-tube problem (blockage, bleeding, sudden displacement).

---

What to eat and what to avoid

• What to eat: Nutrition plan from dietitian; high-calorie formula if needed; thickened liquids if prescribed; small, paced feeds; adequate water per team; reflux-friendly choices; later, purées or smooth textures advanced carefully.

• What to avoid: Thin liquids if swallow unsafe; hard chunks or mixed textures that raise choking risk; pro-reflux foods (mint, very fatty meals) if reflux severe; unapproved herbal “immune boosters”; honey <1 year of age; any feed technique not cleared by the therapists.

---

Frequently asked questions

1. Is there a cure? No cure; care focuses on airway, feeding, seizures, hormones, and development.

2. Can surgery help breathing? Yes—tracheostomy or staged jaw reconstruction can secure the airway.

3. Will my child eat by mouth? Sometimes with therapy; many need a G-tube for safety and growth.

4. Are seizures common? They can be; neurology guides anti-seizure treatment.

5. What about hormones? The pituitary may be affected; endocrine testing guides thyroid, cortisol, and growth treatments.

6. Is development always severe? It varies by brain form and associated issues. Early intervention helps each child reach their best.

7. Are stem cells an option? Not established; only in research settings.

8. Could this happen again in future pregnancies? A genetic counselor can estimate recurrence risk after testing.

9. What is the life expectancy? Highly variable; depends on severity of brain and airway issues and infection risks.

10. Can my baby feel pain? Yes—comfort care and pain plans are important.

11. Will my child go to school? Many can, with individualized supports and therapies.

12. How can we prevent aspiration? Therapist-guided positioning, pacing, thickening, and sometimes G-tube feeding.

13. Which specialists do we need? Neonatology, neurology, endocrinology, craniofacial surgery, ENT, genetics, PT/OT/SLP, nutrition, palliative care.

14. Can we travel? Plan ahead: batteries/supplies, emergency letters, know nearby hospitals.

15. How can we care for ourselves? Accept help, schedule respite, use counseling and peer groups; caring for the caregiver is essential care for the child.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 10, 2025.